Results 241 to 250 of about 10,834,928 (363)

Approaches for Reducing Expert Burden in Bayesian Network Parameterization. [PDF]

Entropy (Basel)
Blomaard BPM, Nane GF, Hanea AM.
europepmc   +1 more source

On A New Arithmetic Function [PDF]

Journal of Mathematics and System Science, 2017
P. Das, K.C. Chowdhury
openaire   +2 more sources

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana, Thuy Vu Craveiro, Thomas C. Marbury, Samuel Oberstein, George J. Atiee, Ben Tao, Takako Shimizu, Yvonne Lau, Malaz A. Abutarif   +8 more
wiley   +1 more source

Tailormade PMMA Spheres: Synthesis and Growth Mechanism. [PDF]

ACS Omega
Thüringer O, Moreira R, Bäumer M, Mendive CB, Gesing TM, Wollbrink A.   +5 more
europepmc   +1 more source

Microtracer‐Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Berzosertib is a small‐molecule ataxia telangiectasia and Rad3‐related protein inhibitor. To assess the clearance mechanism(s) of berzosertib, a Phase 1, 2‐period, open‐label study was conducted in adults with advanced solid tumors who were treated with a single intravenous dose of 210 mg/m2 berzosertib containing approximately 3 µCi of [14C ...
Jayaprakasam Bolleddula, Holger Scheible, Florian Huber, Annick Seithel‐Keuth, Hanno Schieferstein, Deepthi S. Vagge, Nadra Mammasse, Eva Jaks, Jordi Ferrer, Camilo Moulin, Jennifer Dong, Karthik Venkatakrishnan, Zsuzsanna Papai   +12 more
wiley   +1 more source

On Defining Expressions for Entropy and Cross-Entropy: The Entropic Transreals and Their Fracterm Calculus. [PDF]

Entropy (Basel)
Bergstra JA, Tucker JV.
europepmc   +1 more source

Combined Immediate‐Release and Extended‐Release Formulation of Sodium Valproate Provides Stable Plasma Levels for Inhibition of Histone Deacetylation

Clinical Pharmacology in Drug Development, EarlyView.
Abstract A modified controlled‐release sodium valproate formulation (VAL001, test) was compared with an approved enteric‐coated tablet formulation (Absenor, reference). Pharmacokinetics and safety/tolerability were evaluated in healthy subjects to bridge with positive efficacy results from an early‐phase patient trial of valproate in combination with ...
Nikhil Ahuja, Susanna Kääriäinen, Zsófia Lovró, Mia Lundblad, Kristina Drott, Elsa Lilienberg, Marica T. Engström, Karla Saukkonen, Mika Scheinin   +8 more
wiley   +1 more source

Implementation of a Low-Cost Navigation System Using Data Fusion of a Micro-Electro-Mechanical System Inertial Sensor and an Ultra Short Baseline on a Microcontroller. [PDF]

Sensors (Basel)
Winkler J, Badri-Hoeher S.
europepmc   +1 more source

On additive arithmetic functions f(n) for which f(an + b) − f(cn + d) is bounded

, 1983
P. D. T. A. Elliott
openalex   +1 more source

Taste Profile and Relative Bioavailability of Tovorafenib Powder for Oral Suspension and Food Effect of the Tovorafenib Tablet in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract A pediatric‐friendly powder for oral suspension (PfOS) of tovorafenib, a type II RAF inhibitor, was developed for patients with difficulty swallowing tablets. This open‐label, randomized, phase 1 study (QSC205140) evaluated the taste/palatability of PfOS formulations (n = 12), the relative bioavailability of the PfOS versus tablet formulation,
Yang Zhang, Mike Preigh, Jing Wang, Eleni Venetsanakos, Yujin Wang, Elly Barry, Don Corson   +6 more
wiley   +1 more source